CareLit Fachartikel

Phase I Clinical Trial of a Genetically Modified and Oncolytic Vaccinia Virus GL-ONC1 in patients with peritoneal carcinomatosis

UM Lauer, M Zimmermann, U Koppenhöfer, M Bitzer, NP Malek, A Königsrainer, R Möhle, F Fend, C Pfannenberg, JS de Bono, K Harrington, YA Yu, A Röder, AA Szalay · Zeitschrift für Gastroenterologie · 2012 · Heft 08

Dokument
1080495
CareLit-ID
Jahr
2012
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Gastroenterologie
Autor:innen
UM Lauer, M Zimmermann, U Koppenhöfer, M Bitzer, NP Malek, A Königsrainer, R Möhle, F Fend, C Pfannenberg, JS de Bono, K Harrington, YA Yu, A Röder, AA Szalay
Ausgabe
Heft 08 / 2012
Seiten
–
Erschienen: 2012-08-22 00:00:00
ISSN
0044-2771
DOI
10.1055/s-0032-1324086

Zusammenfassung

Introduction: Patients exhibiting advanced stages of peritoneal carcinomatosis that are refractory to standard therapy (i.e., cytoreductive surgery (CRS) plus HIPEC), urgently require new therapeutic approaches like virotherapeutic regimens. Methods: GL-ONC1 is a genetically engineered oncolytic vaccinia virus attenuated by insertion of the RUC-GFP (Renilla luciferase and Aequorea green fluorescent protein fusion gene), beta-galactosidase (lacZ) and beta-glucuronidase (gusA) reporter genes into the F14.5L, J2R (thymidine kinase, TK) and A56R (hemagglutinin, HA) loci, respectively. Results: A first clinical trial…

Schlagworte

Zeitschrift für Gastroenterologie